

## References

### S-209

1. InterQual® Level of Care Criteria 2019. Acute Care Adult. McKesson Health Solutions, LLC.
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms, Version 2.2021.
3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, Version 1.2022.
4. Heidenreich S, Ziagkos D, de Wreede LC, et al. Allogeneic stem cell transplantation for patients age  $\geq 70$  years with myelodysplastic syndrome: A retrospective study of the MDS subcommittee of the chronic malignancies working party of the EBMT. *Biol Blood Marrow Transplant.* 2017;23(1):44-52.
5. Beelen DW, Trensche R, Stelljes M, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): A randomised, non-inferiority, phase 3 trial. *Lancet Haematol.* 2020;7(1):e28-e39.
6. Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. *J Clin Oncol.* 2017;35(11):1154-1161.
7. Kröger N, Iacobelli S, Franke GN, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase iii study of the EBMT (RICMAC Trial). *J Clin Oncol.* 2017;35(19):2157-2164.
8. Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. *Blood Adv.* 2020;4(9):1965-1973.
9. Chatain N, Koschmieder S, Jost E. Role of inflammatory factors during disease pathogenesis and stem cell transplantation in myeloproliferative neoplasms. *Cancers (Basel).* 2020;12(8):2250.

10. Danielson N, Byrne M. Indications for Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome. *Curr Hematol Malig Rep.* 2020;15(4):268-275.
11. Prem S, Atenafu EG, Lam W, et al. Allogeneic stem cell transplant in myelodysplastic syndrome-factors impacting survival. *Eur J Haematol.* 2020;104(2):116-124.